Treatment of multiple endocrine neoplasia 1/2 tumors: Case report and review of the literature

Oncology (Switzerland)

Volumn 84, Issue 3, 2013, Pages 127-134

  Gulati, Anthony P ^a   Krantz, Benjamin ^a   Moss, Rebecca A ^b   Moyal, Wendy N ^a   Tsushima, Dawn A ^a   Mowatt, Kelley B ^a   Schreibman, Stephen ^c   Fine, Robert L ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c MORRISTOWN MEMORIAL HOSPITAL   (United States)

Author keywords

Capecitabine; Liver metastases; Multiple endocrine neoplasia; Neuroendocrine tumors; Temozolomide

Indexed keywords

CAPECITABINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; OCTREOTIDE; STREPTOZOCIN; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; HUMAN; HYPOPHYSIS ADENOMA; MALE; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA 1; MULTIPLE ENDOCRINE NEOPLASIA 2; PANCREATIC NEUROENDOCRINE TUMOR; PARATHYROID ADENOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PROGNOSIS; REVIEW LITERATURE AS TOPIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84870741784     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342961     Document Type: Article

References (45)

1. Yao JC, Hassan M, Phan A, et al: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. Gibril F, Schumann M, Pace A, et al: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83: 43-83. (Pubitemid 38124855)
3. Marx SJ: Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005; 5: 367-375. (Pubitemid 40637828)
4. Lakhani VT, You YN, Wells SA: The multiple endocrine neoplasia syndromes. Annu Rev Med 2007; 58: 253-265. (Pubitemid 46706513)
5. Isacoff W, Moss R, Pecora A, Fine RL: Temozolomide/ capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. J Clin Oncol 2006; 24(18S):14023.
6. Brandi ML, Gagel RF, Angeli A, et al: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671. (Pubitemid 33152604)
7. Oberg K, Skogseid B: The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1. J Intern Med 1998; 243: 471-476. (Pubitemid 28312243)
8. Skogseid B, Eriksson B, Lundqvist G, et al: Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991; 73: 281-287. (Pubitemid 21921870)
9. Vasen HF, Lamers CB, Lips CJ: Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands. Arch Intern Med 1989; 149: 2717-2722. (Pubitemid 20009729)
10. Marx SJ, Stratakis CA: Multiple endocrine neoplasia -introduction. J Intern Med 2005; 257: 2-5.
11. Nehar D, Lombard-Bohas C, Olivieri S, et al: Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60: 644-652. (Pubitemid 38669857)
12. Le Bodic MF, Heymann MF, Lecomte M, et al: Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia, type I. Am J Surg Pathol 1996; 20: 1378-1384. (Pubitemid 26367209)
13. Gibril F, Doppman JL, Jensen RT: Recent advances in the treatment of metastatic pancreatic endocrine tumors. Semin Gastrointest Dis 1995; 6: 114-121.
14. Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006; 141: 765-769, discussion 769-770. (Pubitemid 44268515)
15. Weitz J, Blumgart LH, Fong Y, et al: Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg 2005; 241: 269-276.
16. Ruszniewski P, O'Toole D: Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 2004; 80(suppl 1):74-78. (Pubitemid 39382374)
17. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-1142. (Pubitemid 24118273)
18. Pitt SC, Knuth J, Keily JM, et al: Hepatic neuroendocrine metastases: chemo-or bland embolization? J Gastrointest Surg 2008; 12: 1951-1960.
19. Kvols LK, Buck M: Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987; 14: 343-353. (Pubitemid 18015968)
20. Aparicio T, Ducreux M, Baudin E, et al: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37: 1014-1019. (Pubitemid 32397687)
21. Rinke A, Muller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
22. Oberg K, Kvols L, Caplin M, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973. (Pubitemid 39004355)
23. Ginj M, Chen J, Walter MA, et al: Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005; 11: 1136-1145. (Pubitemid 40175763)
24. Valkema R, Pauwels S, Kvols LK, et al: Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36: 147-156. (Pubitemid 43320450)
25. Brenner B, Tang LH, Klimstra DS, et al: Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004; 22: 2730-2739. (Pubitemid 41103762)
26. Gonzalez MA, Biswas S, Clifton L, et al: Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 2003; 89: 455-456. (Pubitemid 37026423)
27. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-523.
28. Cheng PN, Saltz LB: Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999; 86: 944-948. (Pubitemid 29439847)
29. McCollum AD, Kulke MH, Ryan DP, et al: Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004; 27: 485-488. (Pubitemid 39371944)
30. Moertel CG, Kvols LK, O'Connell MJ, et al: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232.
31. Ramanathan RK, Cnaan A, Hahn RG, et al: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12: 1139-1143. (Pubitemid 32834496)
32. Bajetta E, Rimassa L, Carnaghi C, et al: 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998; 83: 372-378. (Pubitemid 28317819)
33. Bajetta E, Ferrari L, Procopio G, et al: Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002; 13: 614-621. (Pubitemid 34461146)
34. Kulke MH, Stuart K, Enzinger PC, et al: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24: 401-406. (Pubitemid 46630459)
35. Chan JA, Stuart K, Earle CC, et al: Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012; 30: 2963-2968.
36. Kulke M LH, Meropol N, et al: A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETS). J Clin Oncol 2005; 23: 310s (abstract 4008).
37. Kulke MH, Lenz HJ, Meropol NJ, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410.
38. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
39. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
40. Fine RL, Schreibman S, Chen J: Capecitabine and temozolomide: an active regimen for metastatic neuroendocrine cancer. Proc Am Soc Clin Oncol 2005.
41. Skipper HE, Schabel FM Jr, Mellett LB, et al: Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970; 54: 431-450.
42. Kulke MH, Hornick JL, Frauenhoffer C, et al: O-6-Methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009; 15: 338-345.
43. Spiro TP, Liu L, Majka S, et al: Temozolomide: the effect of once-and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001; 7: 2309-2317. (Pubitemid 32751629)
44. Balmaceda C, Peereboom D, Pannullo S, et al: Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 2008; 112: 1139-1146. (Pubitemid 351304600)
45. Strosberg JR, Fine RL, Choi J, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.